LyGenesis is a clinical-stage biotechnology company whose cell therapies use patients’ lymph nodes as bioreactors to regrow functioning ectopic organs. LyGenesis’s lead allogeneic cell therapy program is currently in a Phase 2a clinical trial for patients with end stage liver disease (ClinicalTrials.gov Identifier: NCT04496479). LyGenesis’s drug development pipeline includes cell therapies that can produce an ectopic thymus (for aging and multiple other potential indications), pancreas (for Type 1 diabetes), and kidney (for end stage renal disease). Privately held with investment support from Prime Movers Lab and Juvenescence, and other investors, LyGenesis is headquartered in Pittsburgh, Pennsylvania. To learn more, please visit lygenesis.com.

Harm Reduction Therapeutics is a non-profit 501(c)(3) pharmaceutical company whose mission is to prevent opioid overdose deaths by making low price naloxone available to everyone. Founded in 2017 in response to the high price and access limits of existing naloxone products, Harm Reduction Therapeutics brings together experts in drug development, harm reduction, substance dependence, public health policy, and over-the-counter switches of prescription pharmaceuticals. Our newly FDA approved over-the-counter naloxone nasal spray, RiVive(tm) (naloxone HCl nasal spray 3.0 mg) is now available. For more information, see www.rivive.com.

Morphoceuticals, Inc. is pioneering bioelectric approaches to access anatomical programming that is a core component of our biological operating system. Using proprietary combinations of ion channel and gap junction modulators, we are focused on inducing limb regeneration, improving amputation stump health, promoting organ regeneration, and the treatment of channelopathies. Based in Boston, MA, Morphoceuticals is co-founded by Drs. Levin and Kaplan from Tufts University with funding from Juvenescence, Ltd. For more information see: www.Morphoceuticals.com.

PinneyAssociates helps their pharmaceutical and consumer healthcare clients to reduce their regulatory risk and enhance the commercial value of their products. Science drives all of our work at PinneyAssociates as we help our clients navigate complex regulatory issues and protect public health.

NQ Oncology is a cancer drug development company commercializing a bioamplification mechanism to rapidly and selectively kill tumor cells.

eNT is a healthcare company committed to reducing the harms associated with combustible tobacco products.

MindApps provides mobile electronic Cognitive Behavioral Therapy (CBT) applications for people with major depressive disorder, anxiety disorders, and PTSD looking for real-time support in their daily lives.

Since 2004, NeuroCog Trials has provided consulting, site screening, rater training & certification, and data review services to more than 50 clinical trials in over 25 countries. Our mission is to facilitate the development of novel therapies to enhance cognition.

Cypress is a pharmaceutical company dedicated to the development of innovative drugs targeting large unmet medical needs for patients suffering from a variety of disorders of the central nervous system. Since 1999, Cypress has received FDA approvals for both of the products it brought to the FDA during that period, including for Prosorba™, a medical device for rheumatoid arthritis, and Savella® (milnacipran HCl), for fibromyalgia.

Amylin Pharmaceuticals was engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases. Amylin produced three drugs: Symlin (pramlintide acetate), Byetta (exenatide) and Bydureon (exenatide extended-release). On February 4, 2014, the U.S. FDA approved Myalept (metreleptin), an analog of human leptin, as replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients with congenital generalized or acquired generalized lipodystrophy.

invivodata was a fully-integrated Clinical Outcome Assessment (COA) organization delivering regulatory-proven strategic consulting and practical electronic solutions to biopharmaceutical companies who depend upon patient-centered research.